AllNexImmune Barer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmune NexImmune Raises Gross Proceeds of $126.5M in Upsized IPO after Full Exercise of Underwriters'…levikinzerFebruary 23, 2021
AllNexImmune NexImmune Announces Pricing of Upsized Initial Public Offering GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc., a clinical-stage biotechnology company developing…dantetzlFebruary 11, 2021
AllNexImmune Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Office With more than 25 years of clinical development leadership experience at companies such as Celgene…dantetzlJanuary 18, 2021
AllAsclepix Therapeutics AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME) BALTIMORE, MD, January 5, 2021 – AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to…skylarbennethumJanuary 5, 2021
AllNexImmune NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor Zeldis formerly served as Celgene CMO and CEO of Celgene Global HealthWeber is a renowned…skylarbennethumJanuary 5, 2021
AllCereno Scientific Cereno Scientific terminates agreement with liquidity provider TUE, DEC 22, 2020 16:30 CET Cereno Scientific announced today that the agreement with Mangold…skylarbennethumDecember 22, 2020